Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 85

Similar articles for PubMed (Select 23194360)

1.

Depletion of Tregs in vivo: a promising approach to enhance antitumor immunity without autoimmunity.

Morita R, Hirohashi Y, Sato N.

Immunotherapy. 2012 Nov;4(11):1103-5. doi: 10.2217/imt.12.116.

PMID:
23194360
2.

In vivo maintenance of human regulatory T cells during CD25 blockade.

Huss DJ, Mehta DS, Sharma A, You X, Riester KA, Sheridan JP, Amaravadi LS, Elkins JS, Fontenot JD.

J Immunol. 2015 Jan 1;194(1):84-92.

PMID:
25416807
3.

Regulatory T cells as adjuvant target for enhancing the viral disease vaccine efficacy.

Bayry J.

Virusdisease. 2014 Jan;25(1):18-25. doi: 10.1007/s13337-013-0187-3. Epub 2013 Nov 29. Review.

4.

[Anti-CCR4 mAb and regulatory T cells].

Kurose K, Ohue Y, Oka M.

Gan To Kagaku Ryoho. 2013 Sep;40(9):1150-5. Japanese.

PMID:
24047773
5.

Regulatory T cells: a review.

Dasgupta A, Saxena R.

Natl Med J India. 2012 Nov-Dec;25(6):341-51. Review.

PMID:
23998865
6.

The impact of aging on regulatory T-cells.

Fessler J, Ficjan A, Duftner C, Dejaco C.

Front Immunol. 2013 Aug 6;4:231. doi: 10.3389/fimmu.2013.00231. eCollection 2013.

7.

HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients.

Schmidt HH, Ge Y, Hartmann FJ, Conrad H, Klug F, Nittel S, Bernhard H, Domschke C, Schuetz F, Sohn C, Beckhove P.

Oncoimmunology. 2013 Jun 1;2(6):e24962. Epub 2013 May 15.

8.

Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model.

Tan C, Reddy V, Dannull J, Ding E, Nair SK, Tyler DS, Pruitt SK, Lee WT.

J Transl Med. 2013 Jun 17;11:148. doi: 10.1186/1479-5876-11-148.

9.

CD4+CD25+ regulatory T cells attenuate lipopolysaccharide-induced systemic inflammatory responses and promotes survival in murine Escherichia coli infection.

Okeke EB, Okwor I, Mou Z, Jia P, Uzonna JE.

Shock. 2013 Jul;40(1):65-73. doi: 10.1097/SHK.0b013e318296e65b.

PMID:
23635849
10.

Clinical application of regulatory T cells in type 1 diabetes.

Marek-Trzonkowska N, Myśliwec M, Siebert J, Trzonkowski P.

Pediatr Diabetes. 2013 Aug;14(5):322-32. doi: 10.1111/pedi.12029. Epub 2013 Apr 30. Review.

PMID:
23627860
11.

The interaction between murine melanoma and the immune system reveals that prolonged responses predispose for autoimmunity.

Ngiow SF, von Scheidt B, Möller A, Smyth MJ, Teng MW.

Oncoimmunology. 2013 Feb 1;2(2):e23036.

12.

Regulatory T cells that recognize a ubiquitous stress-inducible self-antigen are long-lived suppressors of autoimmune arthritis.

van Herwijnen MJ, Wieten L, van der Zee R, van Kooten PJ, Wagenaar-Hilbers JP, Hoek A, den Braber I, Anderton SM, Singh M, Meiring HD, van Els CA, van Eden W, Broere F.

Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):14134-9. doi: 10.1073/pnas.1206803109. Epub 2012 Aug 13.

13.

Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia.

Baba J, Watanabe S, Saida Y, Tanaka T, Miyabayashi T, Koshio J, Ichikawa K, Nozaki K, Koya T, Deguchi K, Tan C, Miura S, Tanaka H, Tanaka J, Kagamu H, Yoshizawa H, Nakata K, Narita I.

Blood. 2012 Sep 20;120(12):2417-27. Epub 2012 Jul 17.

14.

Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients.

Mozzillo N, Ascierto P.

Clin Exp Metastasis. 2012 Oct;29(7):801-5. doi: 10.1007/s10585-012-9504-2. Epub 2012 Jul 1.

PMID:
22752507
15.

Immunosuppressive drugs on inducing Ag-specific CD4(+)CD25(+)Foxp3(+) Treg cells during immune response in vivo.

Wu T, Zhang L, Xu K, Sun C, Lei T, Peng J, Liu G, Wang R, Zhao Y.

Transpl Immunol. 2012 Aug;27(1):30-8. doi: 10.1016/j.trim.2012.05.001. Epub 2012 May 14.

PMID:
22613676
16.

CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients.

Rech AJ, Mick R, Martin S, Recio A, Aqui NA, Powell DJ Jr, Colligon TA, Trosko JA, Leinbach LI, Pletcher CH, Tweed CK, DeMichele A, Fox KR, Domchek SM, Riley JL, Vonderheide RH.

Sci Transl Med. 2012 May 16;4(134):134ra62. doi: 10.1126/scitranslmed.3003330.

17.

Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer.

Yao X, Ahmadzadeh M, Lu YC, Liewehr DJ, Dudley ME, Liu F, Schrump DS, Steinberg SM, Rosenberg SA, Robbins PF.

Blood. 2012 Jun 14;119(24):5688-96. doi: 10.1182/blood-2011-10-386482. Epub 2012 May 3.

18.

Ex-vivo expanded baboon CD4+ CD25 Hi Treg cells suppress baboon anti-pig T and B cell immune response.

Singh AK, Seavey CN, Horvath KA, Mohiuddin MM.

Xenotransplantation. 2012 Mar-Apr;19(2):102-11. doi: 10.1111/j.1399-3089.2012.00697.x.

PMID:
22497512
19.

A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.

Sampson JH, Schmittling RJ, Archer GE, Congdon KL, Nair SK, Reap EA, Desjardins A, Friedman AH, Friedman HS, Herndon JE 2nd, Coan A, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, Mitchell DA.

PLoS One. 2012;7(2):e31046. doi: 10.1371/journal.pone.0031046. Epub 2012 Feb 27.

20.

FoxP3+, and not CD25+, T cells increase post-transplant in islet allotransplant recipients following anti-CD25+ rATG immunotherapy.

Hire K, Ngo DK, Stewart-Maynard KM, Hering B, Bansal-Pakala P.

Cell Immunol. 2012;274(1-2):83-8. doi: 10.1016/j.cellimm.2012.01.008. Epub 2012 Feb 6.

PMID:
22364726
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk